D2 Solutions

Overview

D2 Solutions is a boutique market-access and specialty-pharmacy consultancy paired with two in-house SaaS platforms: ComplySuite (accreditation, licensing, regulatory compliance) and UltraTouch (PA automation and patient engagement). Legal name D2 Pharma Consulting LLC, formerly D2 Consulting; founded in 2008 by Dean Erhardt and David Suchanek.

D2 is not a full-service strategy house or a hub operator. It is a specialty-pharmacy and access consultancy that ships software for the compliance and PA workflows it advises on. Buyers searching D2 Pharma Consulting or D2 Consulting should evaluate D2 Solutions as the current operating brand.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, D2 Solutions is evaluated as boutique market-access and specialty-pharmacy consultancy paired with two in-house SaaS platforms: ComplySuite (accreditation, licensing, regulatory compliance) and UltraTouch (PA automation and patient engagement).

Capability	Buyer should compare	D2 Solutions readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core. Specialty-pharmacy and payer-channel orientation; advises on network access, payer contracting, and trade strategy.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Adjacent. Payer-contracting and channel work is documented; confirm rebate/GTN modeling depth in RFP.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Not the core use case. Buyers needing AMCP-grade dossier work should pair D2 with a dedicated HEOR shop.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Confirm network reach in the RFP. Ask for recent payer-research case studies and panel access.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core. Specialty distribution, REMS, 340B, and channel strategy are documented strengths; ComplySuite anchors the regulatory-compliance lane.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Core. Partnerships with Elevate Health Technologies (Sep 2025, UltraTouch Verify in OnePulse Connect) and Mercalis (late 2025) extend launch-execution reach.

Buyer Fit

• Buyer trigger: Specialty-launch teams that need specialty-pharmacy network design, PA workflow automation, and accreditation/licensing infrastructure from one partner instead of stitching together three vendors.
• Best-fit buyers: Emerging biotechs launching a single specialty asset; mid-sized manufacturers consolidating PA, compliance, and patient-engagement tooling; specialty pharmacies seeking accreditation support.
• Less ideal fit: Buyers who need top-of-house HEOR, primary payer research panels, or global market-access strategy.
• Commercial fit: Custom/RFP scoping; ComplySuite and UltraTouch can be licensed independently of advisory engagements.
• Role diligence: Confirm whether ComplySuite/UltraTouch licenses are bundled or separately priced, the named-operator staffing model, and how D2 hands off into hub partners (D2 does not own patient data).

Differentiators

• ComplySuite (AccredComply + LicenseComply + RegComply): Unified specialty-pharmacy accreditation, licensing, and regulatory-compliance platform; few advisory peers ship comparable in-house software.
• UltraTouch PA automation: Production-grade PA workflow with a reported 94% appeals success rate (Jul 2025); now embedded in Elevate Health’s OnePulse Connect.
• Partner-first, no data ownership: D2 does not run a captive hub or own patient data; this is a deliberate competitive posture against larger hubs like AssistRx and CareMetx.
• ProMod Rx acquisition (Apr 2026): Expands patient access and engagement technology footprint.
• Ex-operator senior team: Founders Dean Erhardt and David Suchanek both bring specialty-pharmacy operator backgrounds, which shows up in how the firm scopes specialty-distribution and accreditation work.

RFP Questions

• Which ComplySuite and UltraTouch modules are included in the scope, and which require separate license fees?
• How does UltraTouch integrate with our existing hub, EHR, and payer-portal stack?
• What ComplySuite-supported specialty pharmacies are live today, and what is the accreditation timeline a new SP should expect?
• Which senior operators will lead our engagement, and which prior specialty launches do they cite as analogs?
• How are payer-channel, specialty-distribution, and 340B recommendations validated against current network behavior?
• What is the division of labor with hub partners (AssistRx, CareMetx, others) when D2 is engaged on access strategy?
• What gross-to-net or rebate modeling is in scope, and where does D2 hand off to a HEOR partner?

Recent Activity

• 2026-04 - Acquired ProMod Rx, expanding patient access and engagement technology.
• 2026-01 - Completed security-compliance audit certification.
• 2025-09 - Partnered with Elevate Health Technologies to embed UltraTouch Verify in OnePulse Connect.
• 2025-07 - Launched integrated PA appeals processing with reported 94% success rate.
• 2025-06 - Unified compliance technologies into the single ComplySuite platform (AccredComply, LicenseComply, RegComply).
• 2025 (late) - Strategic leadership alignment with Mercalis (formerly TrialCard) for joint commercialization and patient support.